Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Icos down on earnings update

ICOS was down $6.25 (16%) to $33.24 on 10.3 million shares on Wednesday after disclosing on its second quarter earnings conference call post-market Tuesday that 2004 net loss will be higher

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE